Portland State University

PDXScholar
Dissertations and Theses

Dissertations and Theses

11-29-1995

DNA Sequences Involved in the Regulation of
Human c-MYC Gene Expression by Herpes Simplex
Virus Type 1 (HSV-1)
Shanli Ye
Portland State University

Follow this and additional works at: https://pdxscholar.library.pdx.edu/open_access_etds
Part of the Biology Commons

Let us know how access to this document benefits you.
Recommended Citation
Ye, Shanli, "DNA Sequences Involved in the Regulation of Human c-MYC Gene Expression by Herpes
Simplex Virus Type 1 (HSV-1)" (1995). Dissertations and Theses. Paper 5221.
https://doi.org/10.15760/etd.7097

This Thesis is brought to you for free and open access. It has been accepted for inclusion in Dissertations and
Theses by an authorized administrator of PDXScholar. Please contact us if we can make this document more
accessible: pdxscholar@pdx.edu.

-------.-

...... ._...._....,...___..._

TIIBSIS APPROVAL

The abstract and thesis of

Master of Science
were presented

Shanli Ye

for the

degreein~~~B~i~o=lo~gy;;u._~~~~~~~~~~~~~~~~-

November 29, 1995

and accepted by the thesis

committee and the department.
COMMITIEEAPPROVALS:

, Chair
Robert L. Millette

~L.(raylor
'

David T. Clark

I
!

I
'

l
!

I

.epresentative of the Office of Graduate Studies

DEPAR1MENTAPPROVAL:
Leonard Sirrpson,

Department of Biology

************************************************
ACCEPTED FOR PORTLAND STATE UNIVERSITY BY THE LIBRARY

on4~ /996

...

......

.. _..
........

_,,,

......

...

............

,._

_..

..

...........

...

...

..,.....

...

...........

__

~-

.

ABSTRACT

An abstract of the thesis of Shanli Ye for the Master of Science in Biology presented
November 29, 1995.

Title: DNA Sequences Involved in The Regulation of Human c-myc Gene Expression by
Herpes Simplex Virus Type 1 (HSV-1).

The human c-myc gene is a cellular proto-oncogene composed of three exons and two
introns. Transcription of c-myc is controlled by two promoters, Pl and P2. The activity
of these promoters is regulated by many factors, such as cellular transcription factors E2F,
YYl, and HSV-1 immediate-early proteins, ICPO, ICP4.
Many regulatory elements located both upstream of and between P 1 and P2 have been
identified, and some of these are required for optimum expression of c-myc. In this thesis
research, a region downstream from P2 in the c-myc exon 1 was identified by its response
to transactivation by HSV-1 immediate-early proteins, ICPO and ICP4. The purpose of this

research was to examine this region for regulatory sites that respond to HSV-1 infection.
I hypothesized that after HSV-1 infection, ICPO and ICP4 activate c-myc expression, in
part, through regulatory sequences present in exon 1.
To test for this hypothesis, reporter plasmids containing (I) the c-myc promoter (from 101 bp relative to Pl) and exon 1 coupled to the bacterial CAT gene were constructed.
(ii) The c-myc exon sequences used were either intact (wild-type) or they were constructed

with various deletions.

The activities of these plasmids were examined in transient

expression assays. To analyze protein binding, electrophoretic mobility shift assay (EMSA)
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and completion EMSAs were carried out. The results from these experiments lead to the
following conclusions: (i) ICP4 and ICPO serve as activators, whereas ICP27 inhibits c-myc
gene expression. (ii) The region from +332 to +513 within the c-myc exon 1 contains
an important element required for transactivation of the c-myc gene by HSV-1 proteins.
(iii) Cellular proteins, including factor YYl, bind to the region from +332 to +513 in the

c-myc exon 1.
Although the exact mechanism by which HSV-1 immediate-early proteins regulate cmyc gene expression is still not clear, it gives rise to a possibility that this regulation is
caused by turning on or activation of the cellular regulatory proteins by ICP4 and ICPO.
The cellular proteins in turn activate the c-myc gene expression by interacting with the ciselement downstream from P2.
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DNA SEQUENCES INVOLVED IN THE REGULATION OF HUMAN c-MYC
GENE EXPRESSION BY HERPES SIMPLEX VIRUS TYPE 1 (HSV-1)

GENERAL BACKGROUND
1. PREVIOUS STUDIES ON c-MYC REGULATION
The c-myc gene is the cellular homolog of the v-myc oncogene which was first detected as the
transforming sequence of the avian myelocytomatosis virus (58). In humans, the c-myc gene was
mapped to chromosome 8 (8q24) (5) and it is composed of three exons and two intrans. Exon 2
and exon 3 contain the coding information for the c-myc protein, while exon l is an untranslated
leader that is highly conserved between human and mouse (2) and entirely absent from v-myc (70).
Within the exon 1, there are ~o promoters designated as Pl and P2 which are separated about 170
base pairs (for human c-myc gene) (33).

The products encoded by c-myc gene are two

phosphoproteins that are initiated at independent translational sites (29). These phosphoproteins
are expressed at a low constitutive level in growing cells and arc down-regulated in quiescent and
differentiated cells (38). They are thought to function as transcriptional activators and they arc
involved in the regulation of proliferation, mitogenesis, and differentiation (40). In addition there is
evidence that they play a role in programmed cell death (apoptosis) (52) and in the cytotoxicity of
TNF-a in tumor.cells (37).
Early studies have already revealed that overexpression of c-myc (or deregulation of c-myc
expression) is related to the .tumorigenesis of many kinds of human cancers such as Burkitt's
lymphoma (BL), colon cancer (15), and breast cancer (16).

In BL case, the c-myc gene is

translocated into first intron of the immunoglobulin (lg) heavy chain gene located on the
chromosome 14 [human, t(8,14)]. The immunoglobulin enhancer element located in the intron
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causes the c-myc gene to be over-expressed. This suggested that deregulation of c-myc expression
was important for multistage carcinogenesis.
To understand how c-myc functions in these varied processes, it is important to understand what
factors, both endogenous and exogenous, are involved in regulating the c-myc expression both in
the normal cell cycle and in the tumor cells. We already know that c-myc expression is dependent
on the presence of certain growth factors, e.g. platelet-derived growth factor (PDGF) (38), and on
certain transcription regulatory factors such as E2F (14), YYI (Yin Yang 1) (57), Spl (10), etc.
In 1983, Kathleen Kelly et al found that c-myc mRNA was strongly induced (10- to 40-fold) by
mitogens (e.g. lipopolysaccharides or concanavalin A) in lymphocytes and by PDGF in fibroblasts
(38). Later Nissim Hay et al demonstrated that the 2.3 kilobase pair (kbp) region upstream from
the first transcription start site, P 1, contained both positive and negative regulatory elements which
were involved in regulating c-myc expression by cellular factors (33).
Other previous studies showed that the c-myc expression was regulated at the level of elongation
of transcription (premature tennination of transcription occurs in the first exon of c-myc exon) ( l,
14, 53). Bentley and Groudine demonstrated that when the HL60 cells (human promyelocytic
leukemia cell line) differentiated into granulocytes, by means of treating the HL60 cells with
retinoic acid, the c-myc mRNA level was reduced 10-fold (1). With the nuclear runoff assays, they
showed that this reduction was detected in the transcription of c-myc exon 2 but not c-myc exon 1.
This observation suggested that c-myc transcriptional down-regulation was at the level of
transcriptional elongation rather than initiation, and this transcriptional elongation block occurred
in the first exon of the c-myc gene ( 1).
One of the important findings in the regulation of human c-myc regulation came from a report by
Hiebert et al. They found that the adenovirus pre-early (or immediate-early) protein EIA was able
to activate the endogenous c-myc gene. By using site-directed mutagenesis of the E2F site located
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at about 60 bp upstream of the P2 in the c-myc exon 1, they found that the E 1A transactivation
was mediated by cellular protein E2F (34). This suggested that E2F might play an important role
in activating the c-myc gene expression.
Another important observation is the recent report published by DesJardins and Hay. They
identified and characterized six potential regulatory sites called CT boxes (i.e. cytosine-thymidine
boxes) in the c-myc promoter. Five are located at upstream of Pl and one (CT-Ii) is located
between Pl and P2 (10).

Using a series of deletion mutations along with transfcction and

electrophoretic mobility shift assays (EMSA), they found that these CT elements were binding sites
for Sp 1 and Sp I-related zinc-finger regulatory proteins. Sp 1 binding was found to be responsible
for activating P2-initiated transcription and inhibiting PI-initiated transcription ( 10), and this
promoter usage shift (shift the promoter usage from P 1 to P2) was observed in the normal
individual.
The early studies described above suggest that human c-myc gene expression is regulated at
multiple stages and is regulated by multiple factors, including different cellular regulatory proteins,
growth factors, viral proteins and certain mitogens.

These factors may regulate c-myc gene

expression by different mechanisms (e.g. by activating initiation of the c-myc transcription or
blocking elongation of the c-myc mRNA) The activation by these factors may cause the
overexpression of c-myc gene which can lead to multistage carcinogenesis.

2. GENE REGULATION OF HSV-1
In order to understand how herpes simplex virus type l (HSV-1) infection may be involved
regulation of c-myc gene expression, it is necessary to introduce some general aspects of HSV-1
replication. HSV-1 is a member of the viral family Herpesviridae and is composed of four basic
structures: an envelope with viral glycoproteins, a tegument, a capsid, and a DNA-containing core.
Analysis of the complete sequence of the HSV-1 genome has revealed that its genome has a total
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size 15 2 kbp and contains at least 70 distinct genes (41). Based on the kinetics and characteristics
of their expression, these genes can be divided into three main classes: immediate-early genes (IE,
or a genes), early genes (E, or

p genes),

and late genes (L, or y genes). The expression of these

genes is coordinately regulated and sequentially ordered in a cascade fashion: IE->E->L. The
expression of late (or y) genes requires viral DNA replication. Based on expression time and the
degree of requirement of the DNA replication , the y genes are divided into two subgroups, Yi (for
example, the major capsid protein, YP5, gene) and Y2 (for example, the glycoprotein C, gC, gene).
The y 1 genes, also called
DNA synthesis.

py or leaky-late genes, are late genes start their expression before the viral

However their full expression need the viral DNA synthesis.

Thus their

expression can still be detected (in a lower amount) in the presence of DNA synthesis inhibitors.
On the other hand, y2 genes are expressed after viral DNA replication and they have a high
stringency for viral DNA synthesis. In the presence of DNA synthesis inhibitors, the expression of
y2 genes is almost totally blocked. The relationship between the late genes expression and viral

genome replication is not clear.
The IE class genes are defined as those which can be transcribed in the absence of de novo viral
protein synthesis, and they code for five proteins (infected cell polypeptides) designated as ICPO,
ICP4, ICP22, ICP27, and ICP47.

Three of these immediate-early .proteins, ICP4, ICPO, and

ICP27, are main regulatory proteins for the HSY-1 gene expression (7, 12, 19, 26, 51). ICP4 is a
DNA sequence.,.specific binding protein (11. 20, 44) and a phosphoprotein essential for viral
replication. However, the binding of ICP4 to its consensus binding sites may not be re9uired for its
activation function (65).

The ICP4 regulatory roles in the HSY genes expression have been

revealed in early studies: (i) ICP4 is a major transactivator for HSY early and late gene expression;
(ii) ICP4 represses its own expression and that of other a. genes expression. These ICP4 functions
were demonstrated by the study of ICP4 temperature-sensitive (ts) mutants. Dixon and Schaffer
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demonstrated that, at non-permissive temperature or in the temperature shift experiments, ICP4 ts
mutants exhibited severe impairment in the expression of viral early (VP64) and late (VPlOO,
VP154) genes and the overproduction of the a. genes, such as ICP4, ICP22, ICP27 (12). Later,
similar results were derived from the studying the regulatory roles of ICP4 by using ICP4 mutants
(ts mutants, deletion mutants, and nonsense mutants), assayed by transfection or cotransfcction
experiments, or by detecting and comparing the different HSV mRNA between wild types ICP4
and different kinds of mutated ICP4 (6, 7, 8).

Recently, Gu et al showed that the ICP4

autoregulatory function was related to the cellular protein Sp 1 (26).
Another HSV-1 a. gene essential for viral replication is the ICP27 gene. By using temperaturesensitive (ts) mutants, Sacks et al showed that the growth of ICP27 ts mutants was markedly
impaired at non-permissive temperature, and the expression of three class HSV -1 genes were
altered (overexpression some of a. genes and underexpression some of late genes) (59). These
results indicated that ICP27 played an important regulatory function in HSV replication and it was
required for the expression of HSV late genes. Later, the regulatory functions of ICP27 were
revealed at both the transcriptional and post-transcriptional level (39, 55, 61). Further study on the
post-transcriptional regulatory role of ICP27 revealed that ICP27 could affect mRNA processing
(42, 43, 48, 59, 62), because its regulatory activity appeared to

b~

promoter-independent and

related to the mRNA processing signals present (62). In a system that used the TK (thymidine
kinase)

promot~r

sequence fused to different reporter genes, lacZ and CAT, Sandri-Goldin and

Mendoza found that the ICP27 activity was related to the reporter gene structure, but not the
promoter. They found that pTK-CAT was repressed 12-fold when cotransfected with ICP27, but
there was no effect on pTK- lacZ (62). In agreement with this observation, Hardwicke and SandriGoldin demonstrated that when cells were infected with viral mutants defective in ICP27, the
accumulated levels of at least three spliced host mRNAs were higher than those seen with wild-type
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infected cells (30). This suggested that the host shut off function of ICP27 might be due to an
effect on cellular mRNA splicing.
In contrast to ICP4 and ICP27, ICPO was demonstrated to be required , but not essential, for
viral growth. This was based on the observation that ICPO mutants of HSV-1 were viable in cell
culture, albeit more sluggishly than the wild-type (60). It has been shown in transient expression
experiments that ICPO is the only one of all HSV-1 inunediate-early proteins that was able to
activate all three classes ofHSV-1 genes (15, 16, 22, 19, 54). The activation function ofICPO can
be performed either by itself alone, e.g. in the case of activation of HSV-1 ribonucleotide reductase
(RRl) gene (9), or in a synergistic manner with ICP4. However the activation function of ICPO
seems to be paradox, since in ICP4 mutants (wild type ICPO) , the expression of HSV-1 early and
late genes is not activated (6, 12). This paradox may be explained by the requirement of ICP4 for
the nuclear localization of ICPO (72). In addition, ICPO has been·thought to play an important role
in the HSV-1 latency (68). Besides the functions of the three HSV-1 inunediate-early proteins
described above, these proteins are also involved in regulating the expression of certain cellular
genes (4, 30, 62).

3. PREVIOUS WORK ON ACTIVATION OF c-MYC EXPRESSION BY HSV-1
In 1992, Shin Chen et al reported a cellular regulatory protein, leaky-late binding factor (LBF)
was involved in the activation of HSV-1 major capsid protein VP5 promoter. By using DNA
footprint and s~quence analysis, they found that the LBF target sequence, the leaky-late binding
sequence (LBS}, was very similar to that of a recently described cellular protein, YYI. Using
competition electrophoretic mobility shift assay, they revealed that LBF and YYl might be the
same protein (4). Furthermore, using transient expression assays with HSV-1 superinfection or
cotransfection of HSV-1 immediate-early proteins, they demonstrated that optimal transactivation
of the VP5 promoter depended on an intact YYI binding site (4).

6

Recently, Lisa Mills et al

confirmed that LBF is the same protein as YYl (47).

These reports suggested that HSV-1

immediate-early proteins could activate HSV-1 leaky-late genes, such as the VP5 and gD genes
through cellular factor YYl. On the other hand, YYl has been shown to be an activator of c-myc
gene expression (57). From sequence analysis of the c-myc gene, several potential YYl binding
sites were detected. One is located at downstream from the second promoter in the first c-myc
exon (another one is located around -240 bp). These observations led Dr. Millette to propose that
HSV-1 infection might involved in activating c-myc expression. He and J. Paulson found: (i) The
c-myc expression was activated by HSV-1 infection. ·(ii) HSV-1 treated with UV radiation failed ·
to transactivate c-myc expression (46). These results suggested that some products produced by
HSV-1 had a positive effects on the c-myc gene. Using cotransfection of HSV-1 immediate-early
proteins, they showed that this transactivation was due to the HSV-1 immediate-early proteins,
ICP4 and ICPO. ICP4 appeared to be the major transactivator, since when cotransfected with
ICP4 only, the wild type CAT activity increased about 100-fold as compared with those that were
non-cotransfected (46). An important observation linking c-myc regulation with HSV-1 infection
from Dr. Millette laboratory's is that this regulation may be associated with the cellular protein
E2F. The maps of the plasmids construction for the wild type (+66 wt-Myc-CAT) and mutant
type (+66 mtE2F-Myc-CAT) are shown in Figure I. In the transient expression assay (CAT
assay) for these plasmids, the CAT activity for E2F mutant plasmid decreased about 8.5-fold,
comparing with that for the wild type plasmid, when superinfected with HSV-1. These results
strongly suggested that E2F played an important role in transactivation of human c-myc gene
expression by HSV-1 immediate-early proteins. This is in accord with the early observation that
E2F plays an important role in the regulation of c-myc gene expression (34, 69).
4. SCOPE OF THIS THESIS
Early observations described above showed that (i) cellular regulatory protein YY 1, in
conjunction with HSV-1 immediate-early proteins, might activate the HSV-1 major capsid protein
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VP5 promoter (4); (ii) YYl is an activator for the c-myc gene expression (57); (iii) there is a

!i
potential YYl binding site located at the downstream from the P2. Early studies also revealed

that~

in certain cases, regulatory elements located downstream from the promoter might be involved in
affecting the promoter activity.

Huang et al reported that the VP5 leader (the sequence at

downstream from the VPS promoter) is required for full-level expression by means of the series
deletion and transient expression assay (CAT assay) (35). Another report made by Guzowski et al
also demonstrated that the downstream activation sequence (DAS), a 14 hp element located at
between +22 and +33 (from the transcriptional start site) in the 5'untranslated leader region of the
UL38 gene, was required for the full level of transcriptional activity of the UL38 (late gene)
promoter (28). All these data led to the hypothesis that the region at the downstream from P2 in
the c-myc exon 1 may be also important for the HSV-1 immediate-early protein-mediated c-myc
regulation.
To test this hypothesis, the region in c-myc exon 1 downstream of the P2 was examined. First,
the wild type (-10 l/+513-c-myc-CAT) and mutated plasmids (-10 l/+ 212-Llexon 1-c-myc-CAT and
-101/+332-Llexon 1-c-myc-CAT) were constructed by following ways: (i) The c-myc sequences
upstream of -101 (relative to Pl), in the c-myc-CAT plasmids (in which the c-myc exon 1 was
fused to the bacterial chloramphenicol acctyltransferase gene, CAT, were cut out by endonuclease
digestion. (ii) The desired DNA fragments were isolated and ligated by DNA T4 ligation to
generate -1011+_513-c-myc-CAT and -101/+212-Llexon 1-c-myc-CAT. (iii) The sequences from
+332 to +513 were cut out by endonuclease digestion of wild type c-myc plasmid -10 l/+513-cmyc-CAT. Then the desired large DNA fragment was ligated by using DNA T4 ligase, to generate
-101/+332-Llexon 1-c-myc-CAT. Second, the regulatory roles of c-myc sequences downstream the
P2 in exon 1 were assayed by HSV-1 superinfection, transfection of wild type or mutated c-mycCAT plasmids, and cotransfection of the plasmids containing HSV-1 immediate-early proteins
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gene. Third, DNA probes were prepared, and

el~ctrophoretic

mobility shift assay (EMSA) or

competition EMSA were performed to investigate the possibility that cellular proteins may be
involved in this regulation. The results. from these experiments suggested that DNA sequences
located downstream from the P2 were important for regulation of c-myc gene expression by HSV-1
immediate-early proteins. In this regulation, ICP4 and !CPO appear to function as activators and
ICP27 as an inhibitor of gene expression. These results, combined with the data from early studies
in both Dr.Millette's and other laboratories, suggest that the regulation c-myc gene by HSV-1
immediate-early proteins is mediated through cellular regulatory protein(s) which interact(s) with a
cis-regulatory elements loeated downstream from the P2 start site within exon 1.
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MATERIALS AND METHODS
1. PLASMID CONSTRUCTION (DELETION)
(A) Construction and subcloning of plasmids -101/+212-~exon 1-c-myc-CAT ahd
-10 l/+513-c-myc-CAT.
(1) STRATEGY OF CONSTRUCTION

The plasmids -2.3-~exon 1-c-myc-CAT and -1.3-c-myc-CAT, kindly provided as· a gift from
Nissim Hay of the Ben May Institute in Chicago, contain the upstream c-myc promoter element
from the P 1 transcription start site followed by an undeleted exon 1 or a deleted exon I linked to a
reporter gene called chloramphenicol acetyltransferase (CAT). The plasmid maps and subcloning
steps are diagrammed in Figure 2.

Two µg of each of these two plasmids was digested by

endonucleases Sma I and Cla I (7 units of each) in a final buffer concentration of IX KGB [100
mM potassium glutamate, 25 mM Tris-acetate (pH 7.5), 10 mM magnesium acetate, 50 µg/ul
bovine serum albumin Fraction V (Sigma), 1 mM f3-mercaptoethanol] (61). The larger fragments
from these two plasmids were isolated by the DEAE paper electroelution method which has been
described previously (13). Briefly, the gel was cut at the site that was 3-4 mm in front of the DNA
band, observed under the UV light following ethidium bromide staining. A piece of Whatman
DEAE 81 paper that was slightly wider than the DNA band was inserted into the gel at the site that
was just in front of the DNA band. The DNAs were electroeluted onto the DEAE 81 paper by
running the gel at 200 volts for about 20 minutes. The DEAE paper containing the plasmid DNAs
was transferred into a 1 cc syringe which was previously plugged by small amount glasswool. Tut;
DNAs on the DEAE paper were washed three times using 200 µI each time with solution A [0.1 IV.
NaCl, 0.1 mM EDTA, and 10 mM Tris-HCI (pH 8.0)] by centrifugation each time at 1600 rpm foc
30 seconds. Then the DNAs were eluted three times using 120 µI for each time with solution B [l
M NaCl, 0.1 mM EDTA, and 10 mM Tris-HCI (pH 8.0)]. Finally, the DNAs were recovered by
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means of ethanol precipitation, and dissolved in lX TE [10 mM Tris-HCI (pH 8.
EDTA].
In order to generate a blunt end at the Cla I site, 200 ng of each two larger fra

ents was

treated with 1 unit of Klenow fragment in a final buffer .concentration of l .5X KG

in a total

volume of 15 µl (61). Following incubation for 30 minutes at RT, the four deoxyrib nucleotides
were removed by centrifugation through a 0.9 ml Sephadex G-50 spun column (s un column
chromatography). The column prepared in a 1 ml syringe was equilibrated with TE

buffer [ 10

mM Tris-HCl (pH 8.0), 1 mM EDTA (pH 8.0), 100 mM NaCl], and it was prepared according to
a procedure described previously (61). After the deoxynucleotides were removed,

e fragments

were recovered by ethanol precipitation. Finally about 100 ng of each fragment, wi

blunted end

at both ends, was ligated by incubation with 0.5 unit of T4 DNA ligase in IX T
buffer [50 mM Tris-HCI (pH 7.6), 10 mM MgC12, 1 mM ATP, 1 mM

DJ,

5% (w/v)

polyethylene·glycol-8000]-in a total volume of 20 µI incubated at l6°C for 24 hours.
was to generate the new subclones, -101/+513-c-myc-CAT and -101/+212-8exon J-c-myc-CAT,
containing full-length or a· deletion in exon 1. In generating these two subclones, the ,
Cla I site were removed.

(2) TRANSFORMATION
Competent DM 1 cells, a strain of E.coli that lacks the EcoR I and Ava II m thylases, were
purchased from GIBCO BRL.

The competent cells were transformed with the newly ligatec

plasmids by the method provided by GIBCO BRL. According to this protocol, the transformatior.
was carried out as follows: For each plasmid, 50 µI DM 1 cells and 3 ng of plas id DNA wer~
mixed into a 1.5 ml microfuge tube and incubated on ice for 30 minutes. The mixt res were give-i
a heat-shock at 37°C (water bath) for 20 seconds, and were put on ice again for tw
the mixture were transferred into a clean 15 ml polypropylene tube, and 0. 95 ll terrific brotl

11

[1.2% bacto tryptone, 2.4% bacto yeast extract and 0.4% (v/v) glycerol] was added_ Then the
transformed cells were incubated at 37°C by rotation. Finally, several dilutions of the transformed
cells were plated onto LB plates (I 00 µl of the undiluted culture, 100 µI of a 10 times diluted
culture, and 100 µl of a 100 times diluted culture) and incubated at 37°C for 16 to 20 hours.

(3) DNA EXTRACTION---- MINI AND MAXI PLASMID PREPARATION
Mini plasmid preparation.

The amplified plasmid DNAs (-10 l/+513-c-myc-CAT and -

I 0 II+ 212-.6.exon 1-c-myc-CAT were first extracted by a mini plasmid preparation method termed
the "TENS" method. Briefly, 1.5 ml of overnight culture, grown in the medium of LB containing
ampicillin (50 µg/ml), was by sedimented centrifugation at high speed (about 10,ooq rpm) at 4°C
in a Hermie microcentrifuge. Most of supernatant was poured off (leaving 50 to 100 µI). The
transformed cells were lysed by adding 300 µl TENS solution [10 mM Tris-HCI (pH 7.5), 1 mM
EDTA, 0.4% NaOH, and 0.5% (w/v) SDS]. Then the lysed cells were neutralized

by adding

150

µI 3 M sodium acetate (pH 5.2). · The neutralized mixture was centrifuged in Hermie
microcentrifuge at high speed (about 10,000 rpm) for 2 minutes at 4°C.

The supernatant

containing the plasmid DNAs was transferred into a 1.5 ml microfuge tube. The plasmid DNAs
were precipitated by adding 0.9 ml 100% ethanol, cooling the mixture to less than. -75°C in the
Revco -80°C freezer for 20 minutes, and the centrifugation in Hermie microcentrifug~ at high speed
(about 10,000 rpm) for 5 minutes at 4°C. The supernatant was removed, and the DNA pellet was
washed with 500 µl 70% ethanol. Finally, the plasmid DNAs were dissolved in 3:~ µl of IX TE

[10 mM Tris-HCI (pH 8.0), 0.1 mM EDTA] containing 1 unit of RNase A, and the correcr
subclones were identified by restriction analysis and analytical agarose gel electrophoresis (s~
below).

Maxi plasmid preparation.

All materials including resin columns (Qiagen-tip 500) and

solutions were purchased from the Qiagen, Inc. Plasmid DNAs from large culture (500 ml) we::-e
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extracted by the Qiagen maxi plasmid preparation method according to the procedures described in
the Qiagen plasmid handbook which was provided by Qiagen, Inc. Briefly, 500 ml "Terrific
Broth" [1.2% bacto tryptone, 2.4% bacto yeast extract and 0.4% (v/v) glycerpll medium
containing ampicillin (50 ng/ml) were inoculated with 5 ml of overnight culture of the ~ransformed

E coli cells (DM 1 or HBlOl). These cells were grown with vigorous shaking (280
When they had reached an absorbency of 1 at 600 run (for lower copy plasmids), chl ramphenicol
(170 µg/ml) was added to amplify plasmid DNAs and the culture was further incub ted at 37°C
with vigorous shaking (280 rpm) for 12 to 16 hours. The cells were sedimented in a 250 ml
bottle) by centrifugation at 6,000 rpm at 4°C for 15 minutes and they were resuspendfi with 10 ml
of Pl solution [100 mM µg/ml RNase A, 50 mM Tris/HCl, 10 mM EDTA (pH

8.~].

Then the

cells were lysed by mixing with 10 ml of P2 solution (200 mM NaOH, 1% SDS). A
minutes on ice, the lysate was neutralized by adding I 0 ml of P3 solution [3. 0 M

.c (pH 5.5)].

Cellular debris and E coli genomic DNA were removed by the centrifugation i
centrifuge at 13000 rpm at 4°C for 30 minutes. -Plasmid DNAs were separated fro
RNAs by passing the supernatant solution through a resin column called Qiagen
DNAs were eluted from the column by adding 15 ml of QF buffer (1.25 mM
Tris/HCl, 15% ethanol,).

The eluted DNAs were precipitated with isopropant (see Qiagen

plasmid handbook for detail). Finally, the extracted DNAs were dissolved in 400 t 500 µI of IX
TE and they were analyzed by restriction analysis and agarose gel electrophoresis. The correc1
subcloned plasmids were kept at 4°C. The concentration and total yields of ext
were measured by calculating their absorbency at 260 run, 280 run, and 320 nm ·
DU-40 spectrophotometer.

(4) SELECTING SUBCLONES BY RESTRICTION ANALYSIS
The enzymes used in the restriction analysis were purchased from GIBCO /BRL and Ne-:v
England Biolabs. The extracted subcloned DNAs from both mini and maxi plasJud preparatioas
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were checked by the restriction analysis. Briefly, the plasmid DNAs were cleaved wifr_ restriction
enzymes (endonucleases) so that the circular plasmid DNAs were cut into one linear f::-agment, or
two or three linear fragments. They were also incubated with enzymes which were not able to
cleave this specific kind of the plasmid DNA (e.g. in the subcloned plasmids -101/+513-c-mycCAT and

-101/+212-~exon

1-c-myc-CAT, the Sma I and Cla I sites were removed, so Sma I and

Cla I were not able to cleave these two plasmids). These fragments, as well as the uncut plasmid,
were electrophoresed in an agarose gel (gel concentrations depended on the sizes of the fragments)
using 0.5X TBE (0.54% Tris base, 0.28% boric acid, l· mM EDTA) as the gel ruming buffer.
DNA fragments with the known sizes, e.g. A/Hind III, were used as size markers in the same gel
(when the bacteriphage A. digested by endonuclease Hind III, several known size DNA fragments,
such as 23.1 kbp, 9.4 kbp, 6.68 kbp, 4.36 kbp, 2.3 kbp, 2.1 kbp, and 0.56 kbp, were generated).
After electrophoresis, the gel was stained by ethidium bromide (0.5 µg/ml) for about 16 minutes,
and photpgraphed with the Polaroid. film No.667 under the transmitted UV light using a UV
transilluminator. The .distances of the marker fragments run in the agarose gel were measured, and
a standard curve, which represented the relationship between fragments sizes and distances, was
plotted on semi-log paper according to the sizes and distances of the marker fragments. The sizes
of the sample fragments were determined by measuring the distances of the sample fragments run
in the gel, and then pointing the distances values on the standard curve.

(B) Subcloning for plasmid -101/+332-L\exon 1-c-myc-CAT.
The plasmid map and subcloning steps are diagrammed in Figure 3. Two µg of the plasmid 101/+513-c-myc-CAT was digested with the endonucleases Hind III and Xho I (eac:n of 7 units) ir
a final buffer concentration of IX KGB in a total volume of 30 µl for 3.5 hours at 37°C. The:
larger fragment, the Hind III-Xho I fragment which would be used as the vector, was isolated b;
the electroelution onto a dialysis membrane (dialysis membrane method) (45). Briefly, a slo"',
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which was slightly wider than the width of the band (DNA fragment being isolated), wa:; made just
3 to 4 mm in front of the band in the etbidium bromide stained agarose gel. The Hind III-Xho I
fragment was run onto a piece of nitrocellulose dialysis membrane (whether the DNAs were
completely run onto the membrane need to be checked under the UV light) in a l % agarose gel at
200 volts for about 20 minutes.

The fragment was removed from the dialysis membrane by

running the gel at 200 volts for about 1.4 minutes in the direction opposite to the original gel
running direction. The DNAs in the slots were collected by pipetting them into a 1.5 ml microfuge
tube and recovered by ethanol precipitation. Then 100 µg of the plasmid -10 l/+513-~exon 1-cmyc-CAT were digested again with the endonucleases Hind III and Xho I (each of 350 units) in a
final buffer concentration of IX KGB in a total volume of 550 µl for 4 hours at 37°C. The smaller
fragment, the 487 bp Xho I-Hind III fragment (from the Xho I site to Hind III site) was isolated by
the dialysis membrane method as described above. This fragment (about 2.5 µg) was further
digested by endonuclease of Ava II (10 units) in a final buffer concentration of lX KGB in a total
volume of 30 µI for 3.5 hours at 37°C to generate three fragments: a 266 bp Xho I-Ava II
fragment, a 151 bp Ava II-Ava II fragment, and a 71 bp Ava II-Hind III fragment. All three
fragments were isolated by means of dialysis membrane method as described above. Then 200 ng
of the Hind III-Xho I fragment (as a vector) and 30 ng of the 266 bp Xho I-Hind III fragment were
ligated by using I unit of T4 DNA ligase. In order to generate the blunt ends at the Ava II and
Hind III sites, the ligated mixture was treated with Kienow fragment as described above. After the
Kienow fill-in reaction, the deoxynucleotides were removed by passing through a G-50 column as
described above (61).

The new subclone,

-101/+332-~exon

1-c-myc-CAT, was generated by

ligating both blunt ends of the fragment with I unit of T4 DNA ligase incubated at 37C for 24
hours. In this subcloned plasmid, both the Ava II site and Hind III site were removed.
The transformation, DNA extraction and restriction analysis processes were the same a:
described above except that the strain of competent cells used in the transformation was HB 10 I,
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another strain of E coli, instead of DM 1, and the endonucleases used in restriction analysis (see
table 4).

2. DNA PROBE PREPARATION
Three DNA fragments from c-myc exon 1, the 266bp Xho I-Ava II fragment, the 151bp Ava IIAva II fragment, and the 7lbp Ava II-Hind III fragment, were isolated as described above. These
three fragments were labeled with a.-3 2P-dATP and a.-3 2P-dCTP by means of Kienow fill-in
reaction (see Fig.4) which was described previously (61). Briefly, each of being labeJed fragment
was mixed with radioactive deoxynucleotides (labeled with a.-3 2P-dATP and a.-3 2P-dCTP), nonradioactive deoxynucleotides (dGTP and dTTP), and I unit of Kienow enzyme. The reaction
mixture was incubated for 20 minutes at room temperature (RT). Then the reaction mixture was
chased with I mM of each four unlabeled deoxynucleotides for 10 minutes at RT. The Kienow
fragment activity was inactivated by heating the mixture at 70°C for 10 minutes.

The a.-3 2P-

. labeled or a.-32P-unlabeled deoxynucleotides were removed by passing the reaction mixture through
a G-50 spun column..

The a.-32P-labeled fragments (probes) were recovered by ethanol

precipitation and were dissolved in 100 µI IX TE and stored at -20°C. The radioactivities of the

a.-3 2P-labeled probes were determined in a Beckman LS6500 liquid scintillation spectrometer.

3. CELLS AND VIRUS
Cells and virus used and their propagation were described in the previously publi5hed paper by
Chen et al (4). Briefly, Hela cells (ATCC CCL2) maintained at 37°C under 5% C0 2 atmosphere
in Dulbecco's modified Eagle medium

(DMEM~

GIBCO Laboratory Inc.) supplemented with 10%

(v/v) heat-inactivated fetal bovine serum, penicillin (100 u/ml), and streptomycin (100 u/ml). The
virus, kindly provided by G.S.Read, Loyola, University of Chicago, was the vsh-1 mutant ofHSV1 (KOS) which was defective in the first stage host shutoff function and it was previousl)i
propagated in HEp-2 cell monolayers by Dr. Millette in the Biology Department of Portland State.
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University.
4. TRANSFECTION, COTRANSFECTION AND HSV-1 SUPERINFECTION
The procedures for ti"ansfection, cotransfection and HSV-1 superinfection were almost same as
described in the previously published article (24, 25, 50) modified by Chen et al (4), except that in
the cotransfection assay, the amounts of each plasmid DNA, encoding for HSV-1 immediate-early
proteins (ICPO, ICP4, ICP27), were 2 µg instead of 8 µg (the plasmid pUC18 was used to adjust
the total amount of DNAs to 16 µg which represented the total amount of different kinds of
plasmis in one well). Briefly, Hela cells were seeded in 35-mm well cluster dishes at 3 x 105 cells
per well in 3 ml DMEM-10% IFBS-P/S (4), and incubated at 37°C in the presence of 5% C02.
Twenty hours later, the plasmid DNAs were precipitated by a procedure called calcium phosphateprecipitation.

Briefly, for each duplicate, the appropriate mount of plasmid DNAs being

transfected or cotransfected was.mixed with 0.5 ml of2X HEPES-buffered saline (HES) (280 mM
NaCl, 10 mM KCI; 1.5 mM Na2HP04, 12 mM dextrose, 50 mM HEPES) in a-5 ml polypropylene
tube. Then 0.5 ml. of 0.25 M CaCh was added dropwisely with bubbling and the adding of CaCh
took about 15 seconds. The mixture was incubated at RT for 30 minutes. Then 0.5 ml of calcium
phosphate-precipitated DNA was transfected (plasmid DNAs containing full length cf c-myc exon
l or deletions in the c-myc exon I) or cotransfected (plasmid DNAs containing· HSV-1 immediateearly genes) into Hela cells. Four hours after transfection or cotransfection, the medium was
removed and the cells were shocked by 1 ml glycerol shock solution (15% (v/v) glycerol in
DMEM-10% ICFS] for 1 minute. The cells then were washed 2 times with 3 ml PBS-A (0.14 M
NaCl, 2.7 mM KCl, 4.3 mM Na2HP04, 1.5 mM KH 2P04) supplemented with 3 ml DMEM-10%
IFBS-P/S, and further incubated at 37°C under 5% C0 2. Twenty hours after the transfection or
cotransfection, the transfected cells were superinfected with HSV-1 (described in

eel~

and virus) a1

multiplicity of infection of 3. At the meantime, the mediums for the cotransfected cells werf;
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changed (renewed wi.th the same medium). Both transfected and cotransfected cells were hanrested
40-44 hours after the transfection or cotransfection.

The cells superinfected by HSV-1 were

checked under the microscope, and were harvested when they were approximately 40-5~% rounded
even the time was less than 40 hours. The harvested cells were lysed by the method perfomed by
Nordeen et al (50) Briefly, the cells in each well were rubbed off from well by using a "rubber
'

policeman': and were sedimented by centrifugation in a Hermie microcentrifuge at lov'(er speed at
4°C for 3 minutes. The supernatant was removed by aspiration. Then the cells wrre lysed by
resuspending them in 100 µl lysis buffer [0.25 M Tris/HCI (pH 7.8), 0.25% (v/v) NP;40, 0.005%
(w/v) PMSF], mixing them well, and incubating them on ice for 10 minutes. The mixture was

:

centrifuged in the Hermie microcentrifuge at lower speed at 4°C for 5 minutes. , Finally the
supernatant (lysate) was transferred into a clean 1.5 ml microfuge tube, and the lysates were kept
~

at -80°C (in Revco) for CAT assay .

.5. CAT ASSAY
The CAT assay was described previously (4, 50), and it consisted of measuring ine;orporation of
I

H-acetate (NEN Research Products, Inc.; 3.3 Ci/mmol, 10 mCi/ml) into acetyl-chl~ramphenicol

3

I

I

by using a coupled reactiOn with acetyl coenzyme A synthetase (4, 50). Briefly, for each reaction,
:

43 µI of distilled water, 31.5 µI of 4X CAB [4X CAT assay buffer (400 mM Tris-HCI pH 7.8, 24
mM MgCh,and 300 mM KCI)], 3H-labeled acetyl acid (0.78 µCi/µl), IO µI of 5 mM 1Coenzyme A,
4 µI of 100 mM ATP, and 0.5 µI of 250 mM chloramphenicol were mixed in a 1.5 ml microfuge
tube and pre-incubated for 30 minutes at 37°C. Then 30 µI of each sample lysate was added to
each tube and the contents were incubated at 37°C for 2 hours. After the

incubatio~,

1 ml of cold

benzene was added to each reaction tube, and the contents were completely mixe!d by vigorous
vortexing and inverting. This mixture was centrifuged in Hermie microcentrifuge at high speec
(about 104 rpm) for 2 minutes at 4°C. After centrifugation, 800 µl solution from the. benzene phase
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was transferred into a scintillation vial and dried by evaporation. Finally, the radioactivities of
acetyl chloramphenicol (cpm) was measured in a Beclanan liquid scintillation spectrometer. The
net cpm of acetyl chloramphenicol for each sample was obtained by subtracting the cpm of the
control plasmid (e.g. pUC18) which does not contain the CAT gene.

6. ELECTROPHORETIC MOBILITY SHIFT ASSAY (EMSA)
Both HSV-1 uninfected and HSV-1 infected nuclear extracts (NE) were previously prepared by
Dr.Millette (in Biology Department of PSU) according to the procedures performed by J. D.
Dignam et al (23). In each reaction, NE containing 2 µg of protein, DNA probe (104 cpm), 1-2

mM MgCh, and 1 µg polydldCpolydldC (double stranded polydldC) (Pharmacia Biotech) were
mixed in 0.65 ml microfuge tube. The binding reaction was taken place at RT for 20 tninutes in a
total volume of 16 µI.

Then 1.6 µI of 10% bromophenol blue (BPB) was ad~ed.

A 4%

polyacrylamide gel (PAGE), which was pre-run at 250 volts at 4°C for about 60 minutes, was used
for electrophoresis. The running buffer used in this experiment was IX NRB [0.3% (v/v) Tris
base, 1.43% (w/v) glycine, 10 mM EDTA]. The samples were electrophoresed at 250 volts at 4°C
for 130 minutes. Then the gel was transferred onto a piece of 3 mm paper, covered with a piece of
plastic food wrap, and put on a gel slab dryer for 2 hours to dry. The dried gel was covered by a
RX Fuji film (20.3 x 25.4 cm) which then was exposured for about 13 hours ·at -8CfC. The film
was developed and analyzed for protein binding.

7. COMPETITIONEMSA
Competition EMSAs were run similarly to the EMSA, except that an additional unlabeled 3 3 bp
dsDNA oligonucleotide, whose sequence is CCAGGATCCAGGGCCATCTTGAATGGATCCTGG, was added. This oligonucleotide was named LBS (4) was synthesized by Valium Institute,
Oregon Health Sciences University. It contained a binding site for nuclear protein YY 1, shown in
the underlined part of the sequence (4, 47). The control probe used in this assay was the
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P-

labeled 160 hp DNA fragment from VP5 (HSV-1 major capsid protein) promoter,- which was
previously shown to contained the sequence for the cellular protein YY I binding.

20

RESULTS AND CONCLUSIONS

1. RESULTS

(1) Preparation and analysis of subclones -101/+513-c-myc-CAT and

-101/+212-~exon

1-c-myc-CAT.
To determine whether the sequences in the first exon from P2 are important for the activation of
c-myc gene expression by HSV-1, the plasmids containing deletions in exon 1 of the c-myc gene
were constructed (see Fig. 2). First, plasmids containing only 101 bp upstream of the c-myc
promoter were prepared by excising the region from -2.3 kbp to -101 bp in the plasmid

-2.3-~exon

1-c-myc-CAT, and the region from -1.3 to -101 in the plasmid -1.3-c-myc-CAT (both plasmids
were the gifts from the Nissim Hay in Ben May Institute in Chicago) by digestion with restriction
endonucleases Sma I and Cla I. The large vector fragment was isolated by the DEAE paper
electroelution method. The blunt ends were made at the Cla I site of the vector fragments by the
Kienow fill-in reaction. The two vector fragments were then ligated using T4 DNA ligase to
generate plasmids -101/+513-c-myc-CAT (used as a wild type control) and

-101/+212-~exon

1-c-

myc-CAT. Then the subcloned plasmids were transformed into competent E coli cells,. screened by
mini plasmid preparation. The correct subcloned plasmid DNAs were extracted by maxi plasmid
preparation. The total yields from a 500 ml culture was 292 ug for -10 l/+513-c-myc-CAT and
304 ug for -101/ +212-~exon 1 c-myc-CAT. ·
The resulting plasmids were examined by restriction analysis (see Fig.5 for restriction map).
First, both -1011+513-c-myc-CAT and -101/+212-~exon 1-c-myc-CAT were digested by
endonuclease Hind III, Hind Ill/Pvu I, EcoR I, and Sma l/Cla I. The digesting mixtures were run
in a 1% mini gel (Fig.10). The mini gel showed that the number of observed bands resulted from
this digestion is consistence with the number of expected bands (Table 1), and the sizes of observed
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bands arc approximately estimated to be correct according to the sizes of marker bands I sizes can
not be accurately measured in mini gel) (Fig.10).

To confirm the mini gel results, khese two

subcloned plasmids were examined in two standard agarose gels, 0. 9% gel for linear Iform and
1.2% gel for diagnostic digestion (most important evidence) by EcoR I and EcoR I/No1 I (Fig.13
and Table 2). These results indicated that both sizes and numbers of the bands produced coincided
with those expected from restriction maps. Therefore they appeared to be the correct lsubcloncs.
To confirm the deletion part of the subclone -101/+212-.6.exon 1-c-myc-CAT, DNA rcquencing
was carried out. Although part of sequences upstream the Nea I site (+212 hp) could, be read, it
failed to show the deletion part. Therefore an alternative experiment, the restriction
small fragment [from Not I site (+22) to Hind III site] spanning the deletion part, wasjperformed.
Thus the Not I-Hind III fragment (see Fig.5) was isolated and further analyzed the 4igcstion of
endonucleases Pvu II, Alu I, Xho I, Hinf I, Ava I and Ava II. This analysis showfd that this
fragment was able to be digested by Xho I only, and it could not be digested by Pvu 11,/Alu I, Hinf
I, Ava I and Ava II (Fig.11). This result was consistent with the data shown on the Rlasmid map
(see Fig.5), from Nissim Hay in Ben May Institute in Chicago (32), and confirmeli that the 10 II+ 212-.6.exon 1-c-myc-CAT was the correct subclone.
(2) Preparation and analysis of subclone -101/+332-.6.exon 1-c-myc-CAT
To further determine the more specific region within the c-myc exon 1 which was re ponsible for
HSV-1 immedi3:te-early proteins mediated human c-myc regulation, the region from 332 to +513
(181 hp), and the adjacent 40 hp up to Hind III site in the plasmid -101/+513-c-m c-CAT was
removed by the endonucleases Ava II and Hind III as described above. The subclon -101/+332.6.exon 1-c-myc-CAT was generated by first ligating the vector with the 266 hp

o I- Ava II

fragment by T4 DNA ligase (see Fig. 3), treating Kienow fragment to make both ends blunt, finally
ligating both blunt ends together with T4 DNA ligase.
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The plasmid DNAs of this subclone were prepared by the Qiagen maxi plasmid preparation
method (as described above). The total yield from a 500 ml culture was 360 ug. As with the other
subclones, this subclone was examined by restriction analysis with the endonucleases Hind III,
EcoR I, Not I, and Xho I (see Fig.5 for the restriction map) first in a 1% mini agarose gel (Fig.12).
The mini gel results showed that the number of observed bands is consistence with the number of
expected bands (Table 1). In Fig.12, it also showed that the sizes of the bands are approximately
measured to be correct according to the sizes of marker bands (the accurate size can not be
measured in mini gel).

To confirme the mini gel results, this plasmid was examined in two

different concentration standard agarose gel, 0.9% for· linear form and 1.2% for diagnostic
restriction (most important evidence). The standard gel is shown in (Fig.10 and 13) and the

si~es

of bands in standard gel were measured (Table 2). The results (shown in Table 1, Table 2, Fig. IO,
Fig.12, and Fig.13) indicate that both sizes and numbers of the bands agree with those predicted
from the restriction map. Therefore -10 l/+ 332-D.exon 1-c-myc-CAT subclone is correct.

(3) Sequences located at downstream from the P2 in the c-myc exon 1 contain the
responding elements for the ICP4 and ICPO mediated activation
To determine whether there is a element located downstream from the start site in the c-myc
gene, P2, which is activated by HSV-1 immediate-early proteins, the subcloned plasmids 101/+513-c-myc-CAT (as wild type control containing -101 to +513 of c-myc) and -101/+212D.exon 1-c-myc-CAT (containing -101 to +212 of the c-myc) were assayed separately two times in
a transient expression assay system (CAT assay). The linear maps are shown in Figure 5. To test
their abilities to be transactivated by HSV-1, the HeLa cells were transfected with .each of these
plasmids, and 20 hours later they were superinfected with HSV-1 at a multiplicity of 3. Parallel
control cultures remained HSV-1 unsuperinfected. Twenty to twenty four hours after
superinfection the cells were harvested and their lysates were analyzed for CAT enzyme activity.
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The results are shown in the Figure 6 and the Table 3. These results showed that the CAf activity
increased 5. 7-fold for the wild type c-myc plasmid -10 l/+513-c-myc-CAT when HJV-1 was
superinfected. Similarly, a 3.9-fold and a 1.9-fold increase were observed in the mutant (deletion
in the first exon of c-myc) c-myc plasmids -101/+212-6exon 1-c-myc-CAT and -101/+
1-c-myc-CAT, respectively. Furthermore, when the CAT activity was compared to that
type - I 011+5 I 3-c-myc-CAT in the presence of HSV- I superinfection, a 5. 2-fold and la 6 .2-fold
reduction was observed in the cells transfected with the mutant c-myc plasmids -101/+212-6cxon
1-c-myc-CAT and -101/+332-6exon 1-c-myc-CAT, respectively. When compared to th
level set at 100%, the represented relative CAT level of 19.2% and 16.1 to the -101/ 212 and 101/+332 deletion respectively (Fig.6, Table 3). These results were accord with the pr vious data
from Dr. Millette's laboratory that c-myc gene expression was strongly activated by HSV-1
infection, and t:hey indicated that the sequences within the first exon of c-myc gene ar

1

for activation by HSV-1 infection.
According to previous results from this laboratory (46), the major activation is
HSV-1 immediate-early proteins ICP4 and ICPO. To investigate the involvement of
the +332 to +513 bp region in this activation, the activity of the subclone -101/+33
myc-CAT was compared with that of the wild-type promoter in two separate cotransfe
One reason to speculate the region from + 332 to +513 of the first exon of c-myc is i
the ICP4 and IGPO mediated activation is that it contains a potential binding site fo
regulatory protein YY I at about +4 5 3 bp. This cellular regulatory protein was previojsly shown to
be involved in activating the murine c-myc promoter (57) and the HSV-1 VP5 pro
investigate this, HeLa cells were transfected with wild type and exon I

dele~ions oJc-myc-CAT,

and simultaneously cotransfected with piasmids expressmg HSV-1 IE protems 1t cinta1ns. The
results of the cotransfection assays (see Fig.7 and Table 4) demonstrate that, comp
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non-cotransfected cells (transfected with -10 l/+513-c-myc-CAT only), the CAT activatics of the
wild type c-myc plasmid -101/+513-c-myc-CAT increased 13.7-fold when cotransfectcd with
ICP4, 16.7-fold when cotransfected with ICP4 and ICPO, and it was reduced 1.5-fold when
cotransfected with ICP4, ICPO, and ICP27.

Relative to the wt (-101/+513) set at 100%,

cotransfection of ICP4 alone was 78.3%, and ICP4, 0, and 27 was 5%. On the other hand, the
similar comparison in the c-myc mutated plasmid showed that the CAT activity of the plasmid 101/+332-~exon

1-c-myc-CAT increased 2.1-fold when cotransfected with ICP4, a1d 4.5-fold

when cotransfected with ICPO, and it was reduced 1.1-fold when cotransfected with all three HSV1 immediate-early proteins. Relative to the wt CAT plasmid induced with ICP4/ICPO (as I 00%),
this deleted plasmid (-101/+332) gave the CAT level of 2.5%, 16.0%, and 0.9% when
cotransfected with ICP4, ICP4/ICpO, and ICP4/ICPO/ICP27, respectively. These results lead to
two suggestions: (i) The region from +332 to +513 contains an element required for c-myc gene
activation by HSV-1 immediate-early proteins.

(ii) ICP4+ICPO together

provid~

maximum

transactivation, ICP4 appears to provide the major, single transacting effect, and ICP27 functions
to inhibit its expression.

( 4) Are there any binding sites for cellular regulatory proteins in the region from +33 2 to
+513 in the first exon of c-myc gene?
To determine whether any cellular regulatory protein(s) bind(s) to the c-myc exon I reg10n
between +66 and +513 hp, electrophoretic mobility shift assays were carried out with three c-myc
fragments spanning this region. These fragments were 266 hp Xho I-Ava II fragment [from +66
hp to +332 hp (see Fig. 5)], 151 hp Ava II-Ava II fragment [from +332 hp to +483 hp (see Fig.
5)], and 71 hp Ava II-Hind III fragment [from +487 hp to +513 hp, and up to Hind III site at the
start site of the CAT gene (see Fig. 5)].

Because of the data derived from CAT assay, we

emphasized examining the region from +332 to +513 in the c-myc exon I. The results of the:
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EMSA (Fig.8) showed: (i) There are two major shift bands observed in the lanes for t e 266 hp
Xho I-Ava II probe (Fig.8, lane 11 and 12). (ii) There were three shifted bands (two m jor bands
and one minor band) observed both for the 151 hp Ava II-Ava II probe which contains

potential

binding site for transcription factor YYl (Fig.8, lane 6 and 7), and 71 hp Ava II-Hin III probe
(lane 2 and 3). Previous studies have shown that HeLa cell nuclear extracts form 2
YY 1, one representing a YY I degradation product (4). Therefore two of these bands could be
caused by YY 1. To determine if any of these bands were formed by YY 1, the competitikm EMSAs
were carried out. The results showed (Fig.8): (i) Positive control probe (VP5) has two
caused by YYI binding. They appear to be lowered in intensity when the LBS is preseµt. (ii) The
bands observed in the 266 bp probe are only slightly competed. (iii) The intensity of khese bands
did not diminished when the radioactive 151 hp Ava II-Ava II probe was competed wit1a290- and
400-fold molar excess of LBS, a unlabeled 33 bp dsDNA fragment containing a YYI binding site
(Fig.8, lane 8 and 9). This indicated that these shifted bands were not due to the

ii

binding.

(iiii) Three bands (two major bands and one minor band) were observed when 71 b
used. The two major shifted bands disappeared when competed with a 400-fold molar excess of
LBS, indicating that these bands were due to binding of the cellular regulatory protein,/YYI (Fig.8,
lane 4). This observation was confirmed by early data from competition EMSAs usirk 32P-labeled
222 bp Ava II-Hind III fragment (from the Ava II site at +332 within c-myc exon l to
and see Fig.5 for map). In this experiment, C2, a dsDNA fragment not containing
site, was used as a negative control oligonucleotide.

1 binding

The results showed that t1e two bands

supposed to be caused by YYI binding diminished when the 222 bp Ava II-Hind II probe was
competed with LBS, but they did not diminished when the probe was competed wi
Thus, the possibility that the two bands were caused by non-specific proteins
excluded. However, from the sequence analysis, there was no YYl consensus bin

26

found in this region , indicating that YY I was not a factor involved in HSV-1 immediate-early
proteins mediated regulation of human c-myc gene.

This looks like somewhat contradictory.

There are two possible explanations: (i) the 40 bp vector sequence (see Fig.5) constructed by Hay
contains a YYI binding site; (ii) the region from +483 to +513 might contain a non-consensus or
high degenerated YYI binding site. According to the second explanation, the role of the cellular
protein YYI in the HSV-1 immediate-early proteins mediated c-myc regulation still could not
excluded.

2. CONCLUSION
The results from these studies lead to the follow conclusions:
( 1) HSV-1 immediate-early proteins are regulators for human c-myc gene expression in transient
assays. ICP4 is the major transactivator, ICPO is a minor transactivator, and ICP27

s~rves

as an

inhibitor of the c-myc gene expression.
(2) The region from +332 to +513 in the exon I of the c-myc gene contains a seque:oce which is
responsible for the ICP4 and !CPO mediated transactivation of human c-myc gene expression
[other important regions upstream of the P2, such as E2F site, were also identified in previous
studies (46)].
(3). The data from my EMSA ·results suggest that at least one cellular regulatory protein is
involved in viral regulation of the human c-myc gene through sequences in exon 1.
(4). From the data derived from the EMSA and competition EMSA, I conclude that the cellular
regulatory protein YYl is not likely involved in the HSV-1 mediated regulation of human c-myc
gene through the exon 1 sequences. However, there is a possibility that a non-consensus YYl
binding site may be involved for the regulation by this region of the c-myc gene.
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DISCUSSION .
Early studies revealed that c-myc expression is regulated, either positively or negatively, , by
many factors at different stages (e.g. it may be regulated at level of initiation of transctiption or at
level of elongation of transcription). Many target sequences for cellular transcription factors have
been identified in the c-myc promoter in the region between 2.3 kbp and the transcfription start
sites, Pl and P2 (10, 33). Recently Dr. Millette and J. Paulson found that HSV-1

i~ediate-early

proteins (mainly ICP4) could activate the expression of c-myc gene (46). Their s·
showed that this activation was related to a target sequence for cellular protein E2F bPiding. This
binding site was located between P 1 and P2 (around + 117) (46). Consistant with the results shown
by Millette and Paulson, the experiments presented here also demonstrate that the
gene is regulated by the HSV-1 immediate-early proteins. In these experiments, adclitional target
sequences for HSV-1 immediate..early proteins (ICP4 and ICPO) mediated activation i~ identified in
the region downstream from P2 (between +332 and +513 hp), within the first exonjof the c-myc
gene. The exact mechanism involved in this regulation was not established.
We have already shown that three immediate-early proteins, ICP4 ICPO, and ICPl7 play a role
in regulating both viral and cellular genes. All three of the HSV-1 immediate-early proteins are
nuclear phosphoproteins that are able to regulate the expression of other genes. ICPj4 is the major
transcriptional activator of HSV-1, although it represses its own expression (6, ll, 26). It has
been reported to bind DNA nonspecificically (21 ), but it also binds to some of its $get sites in a
sequence-specific pattern.

Its high affinity binding sites have been identified! as ATCGT-

CNNNNYGRC (where R is purine, Y is pyrimidine, N is any base (20, 44), and all of its binding
sites conform to the consensus sequence RTCGTCNNYNYSG (where R is pur!e, Y is pyrimidine, Sis C or G, and N is any base) (11). Early studies showed that the activa on function o:·
ICP4 is independent on the specific binding. Imbalzano suggested that ICP4 m~y activate the

28

·expression of HSV-1 early and late genes by a mechanism that does not require sequence-specific
binding (36). Similar to this suggestion, other laboratories demonstrated that the mutations in
either the ICP4 target sequence or in the ICP4 binding domain did not affect its transactivation
function (64, 65).
Early studies and my data showed: (i) ICP4 binding concensus binding sites were not found in
the region from +332 bp to +513 bp within the exon 1 (J. Paulson, personal communication), and
the binding ofICP4 to its target sequence might not be required for its activation function. (ii) The
data derived from transient expression (CAT assay) showed that the region from +332 bp to +513
hp in the first exon of c-myc was important for the regulation of c-myc gene expression by HSV-1
infection. (iii) The data from EMSA and competition EMSA demonstrated that some cellular
proteins bound to the DNA sequences in the region from +332 bp to +513 bp. (iiii) The early data
from this laboratory (46) and the data in this paper showed that the ICP27 inhibition of c-myc
expression seemed mainly to inhibit the ICP4 mediated transactivation. Early studies also revealed
that ICP27 was involved in the secondary host shutoff process. Taken together these observations,
it is reasonable to· speculate that cellular factor(s) is/are involved in the ICP4 mediated activation
of human c-myc gene expression at the level of transcription.

This speculation may also be

supported by the early studies that human c-myc expression depends on the presence of cellular
proteins. However, the previous studies, described above (40, 71, 72), might also give rise to the
possibility that ICP4 might bind to a site which was of the low affinity or high degeneracy type=
and the human c-myc gene expression might be activated by this binding. Therefore the possibili~
that ICP4 directly transactivates human c-myc gene expression still can not be excluded.
In contrast, among these three immediate-early proteins, ICPO is the only one that activates al
three kinetic classes (ex.,

p, y) ofHSV genes, without apparent DNA sequence specificity (17,

I~,

49, 51, 54). It is able to further enhance the expression of any gene that exhibits a basal level cf
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11

transcription (71).

There are many reports which showed that ICPO exhibits

j

synergistic

transactivation with ICP4 (71, 72), and our cotransfection assay results are concord t with these
reports. This synergistic transactivation may require the physical interaction betwedn ICPO and
ICP4 (71). ,Recent study also revealed that ICP4 appeared to be required for Ithe nuclear
localization of ICPO (72)
ICP27 is another HSV-1 immediate-early protein involved in the regulation otj c-myc gene
expression. Although early showed that ICP27 alone was able to inhibit the expresJon of c-myc
gene, early data (46) and my experiments demonstrated that ICP27 mainly inhibited I
c-myc activation. Previous study revealed that ICP27 is involved in the secondary

s~ge

shutoff of

the host proteins synthesis (31). When cells were infected with HSV-1 mutants defJctive ICP27,
the shutoff host protein synthesis was greatly reduced.(59). Other studies showedl that ICP27
regulated cellular genes expressions post-transcriptionally (31, 62, 67), and that retlation (both
activation and repression) was not dependent on the target gene promoters, but on th ir processing
signals (62). For the inhibitory activity of ICP27, the presence of intrans in the target genes were
required. (62). These observations suggest that the inhibitory function ofICP27 we

ve observed

in the regulation of human c-myc gene might also occur at the post-transcriptional 1 vel. If this is
true, it is reasonable to consider the possibility that the mechanism of ICP27 -repre sion of c-myc:
gene expression might be due to inhibition of action of certain cellular proteins.

ese proteins,.

activated by ICP4, possibly and/or ICPO might be required for activating human
binding to the region from +332 to +51_3 within exon I. These possibilities support

~e speculatior

that cellular regulatory factor(s) is/are involved HSV-1 mediated regulation of hurr)an c-myc gem=
expression. ICP27 can also inhibit the nuclear localization of ICPO (72), and redluce the ICP4ICPO synergy. This would therefore inhibit the ICP4-ICPO synergistic activation.
In summary, my experiments demonstrate that the HSV-1 immediate-early
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ICP4, ICP27 are the regulators of the human c-myc gene. The results of cotransfection experiment
showed that the relative CAT activity observed for wild type c-myc plasmid is 1E% for noncotransfection, 78.3% for the cotransfection of ICP4 alone, 100% for the cotra...,sfection of
ICP4/ICPO, and 5% for the cotransfection of ICP4/ICPO/ICP27. The relative CAT activity for the
mutated c-myc plasmid -101/+332-8exon 1-c-myc-CAT is 1.7% for non-cotransfection, 2.5% for
cotransfection of ICP4 alone, 16% for cotransfection ofICP4/ICPO, and 0.9% for cotransfection
of ICP4/ICPO/ICP27 (the CAT activity observed in wild type c-myc plasmid cotransfected with
· ICP4/ICPO is set as 100%). Therefore ICP4 is the major transactivator whereas ICP27 inhibits the
expression of the c-myc gene.

This inhibition was observed either at basal level of c-myc

expression (minor effect) (46) or in the ICP4 mediated c-myc activation (major effect). This
implied that cellular proteins may be involved, because of its host shutoff function. The
cotransfection results, together with the HSV-1 superinfection results, also suggest that one of the
responding element in the c-myc exon l is located at the region from +332 bp to +513 bp
downstream of the P2. In addition, the results from the EMSA and competition EMSA show that
some cellular proteins bound to this region (Picture 1). This also implies that cellula1 proteins may
be involved in this regulation.
Taken together with the observations from Dr. Millette's previous studies (46) and earlier studies
on the HSV-1 immediate-early proteins (31, 36, 46, 59, 62, 65), my results suggest that cellular
regulatory factor(s) may be involved in the ICP4 mediated human c-myc gene activation.
Hypotheoretically, ICP4 may activates cellular protein(s) which in turn bind(s) to their ta~ge1
sequences in the c-myc gene and activate(s) c-myc gene expression. The exact mechanism o:·
HSV-1 immediate-early proteins mediated regulation of c-myc gene is still unclear and it need;.
further investigation.
In my opinion, Further study will include DNA footprinting. This experiment will give info..
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mation of the exact cellular proteins binding sites. From the data derived from the DNA footprint~
these binding sites could be used to compare with the binding sites of known proteiru. Thus the
possible kinds of proteins bound to the c-myc gene may be obtained.
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Subclones
Enzyme

-1O1 /+513-c-Myc-CAT
Hind

III

I

Number of
observed
bands
Number of
expected
bands

Hind III/

Pvu I

I

1011+212-~xon

Sma II
Cla I

Hind

III .

I

Pvu I

-101/+332-~exon 1-c-Mvc-C.ttT

1-c-Mvc-CAT

Hind III/

I

Sma I/
Cla I

Hind III

I Xho I I Pst I

I Kho II
bst I

2

no cut

2

no cut

no cut

12

2

no cut

2

no cut

no cut

:2

Table 1. Results of restriction analysis in mini-gels for the subclones -101/+513-c-Myc-CAl" -101/+212Aexon 1-c-Myc-CAT, and -101/+212-~exon 1-c-Myc-CAT. The results indicate that t number of
observed bands are consistence with that of the expected bands. See Fig. IO, and Fig.12 for ~gel.

Subclone
Enzyme
Number of
observed
bands
Number of
expected
bands
size of
observed
bands
size of
expected
bands
conclusion

-101/+513-c-Myc-CAT
Pst I
I EcoR I
I EcoR II
Not I

-101/+212-~xon

Pst I

I EcoR I

1

2

1

2

1-c-Mvc-CAT
I EcoR II
Not I

-101/+332-&xon 1-c-M+c-CAT
Pst I
I EcoR I I EcoR l/
Not I

I'
I

1

2

1

2

6.3 kbp

l

I

3 (see••)

0.94 kbp I 0.80 kbp
and a lar- • and a large
size band·.

6.3 kbp

2

0.93 kbp
and
5.37,kbp

size band".

1146 bp;0.79kbp,
and
5.37 kbp

2

3 (see·°)

6.0 kbp I 0.61 kbp
and a lar-

1
6.0 kbp

ge size
band·.
0.63 kbp
and
5.37kbp

0.46 kbp
and a large size
band·.
146 bp,-0.484 kbp,
and
5.37 kbp

1

2

1

2

6.10 kbp

6.08 kbp

I
I

2

: 3 (see"")

0.71 kbp
and a large size
band·.
0.71 kbp
and
5.37 kbp

0.55 kbp
and a large
size band"

1

'146 hp,""
'0.564 kbp,
and 5.37
'kbp.

:

all subcloned plasmids are correct

:

Table 2. Results of the restriction analysis of the subcloned c-myc plasmids -101/+513
101/+212-L\exon 1-c-Myc-CAT, and -101/+332-L\exon 1-c-Myc-CAT in two different co
agarose gel (0.9% and 1.2%).. The results indicate that both the number and sizes of obs
same or very close to those of the expected bands. The most convincing evidence that t
plasmids is derived from the measurement and comparison of the diagnostic bands. The
in these bands represent the deletion parts in the exon 1. The gels are shown in Fig.IO
Fig.13 (1.2% gel for the diagnostic digestion by EcoR I and EcoR I/Not I).

c-Myc-CAT, centrations of
' ed bands are
ey are correct
~ze differences
0.9% gel) and

*The sizes of the larger fragments .in Fig.13 can not be measured because of the conc~htration of the:
agarose gel (1.2%). The larger marker DNA fragments can not be separated welll at the higher
concentration gel.
1

··The 146 bp fragment in Fig.13 is too small to be detected. The reason to examine the Ec;QR I/Not I band
is that this band is really important for the diagnostic purpose.
I:
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l

Plasmids

HSV-1

-101 /+513-c-myc-CAT

+
-101/+212-Aexon 1-c-myc-CAT

+
-10 l /+513-c-myc-CAT

+
-101/+332-Aexon 1-c-myc-CAT

+

CAT Activity (pmol 3H0Ac Chloramphenicol/
mg Protein/h
5.8 x 103
39.0 x 103
3
1.9 x 10
7.5 x 103
7.2 x 102
31.0 x 103
3.2 x 102
5.1x102

percentage of1duced
CAT activity the wild
type c-myc pl mid (%)
14.9
100.0
4.9
19.2
23.2
100.0
10.3
16.1

Table 3. Relative CAT activities for the the wild type and mutated c-myc plasmids -101/+f 13-c-mycCAT, -101/+212Aexon 1-c-myc-CAT, and -101/+332-Aexon 1-c-myc-CAT in two separ te HSV-1
superinfections. The CAT activity represents pmol chloramphenicol acetylated/mg protein/h. The CAT
activity of wild type -101/+513-c-myc-CAT superinfected by HSV-1 is set as 100%.

Transfected plasmid

I

Cotransfected
plasmid

I pmol
3H OAC Chloram- I percentage o induced
phenicoUmg Protein/h
CAT activity f the wild
smid %

-1 Ol/+513-c-Myc-CAT

-101/+332-~exon

1-c-Myc-CAT

ICP4
ICP4/ICPO
ICP4/ICPO/ICP27
ICP4
ICP4/ICPO
ICP4/ICPO/ICP27

9.4Xl0
l.2Xl04
6.0X102
3.0XIO
2.0XlO
l.1X10 2

78.3
100.0
5.C

2.:
16.(

o.o

Table 4. Relative CAT activities for the the wild type and mutated c-myc plasmids -101/£513-c-MycCAT and -101/+332-Aexon 1-c-myc- CAT in two separate cotransfection experiments. The AT activity
represents pmol chloramphenicol acetylated/mg protein/h. The CAT activity of wild type 101 /+513-cmyc-CAT cotransfected with ICP4/ICPO is set as 100%.
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1•0

-353 -240

p2

pl

fos/fun
Octyy1

~

5Sp1 -101

Exon I
/

"'-.

~52--103' /

+1 +66

·
+66 wt-Myc-CAT
+66

+t7 ~
4

E2F

CTI

+117

+134

~

0-•--11-----E-xo_n_l_ __,I
+174

P2

mtE2F
+66 mtE2F-Myc-CAT

Exon I
+17.4

+513

Fig.1. The maps of the wild type plasmid of +66-c-myc-CAT and the E2F-site mutat<fd plasmid,
c-myc+66 mtE2F-CAT.
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-1.3

-2.3-aexon 1-~Myc-CAT

-1.3-c-Myc-CAT
-

....-..:+174

c-Myc
.xon I
513
Hind Ill

CAT

-101/+513-c-Myc-CAT

-101/+212-Aexon 1-c-Myc-CAT

Fig.2 Map and steps in constructing wild type plasmids -101/+513-c-myc-CAT and
-101/+212-Liexon 1-c-myc-CAT. The vector plasmid is pBR322.
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+174

.---r--

40bp

CAT

+66

+66

~

Xhol
Hindlll-Xhol

·r

t513
(

Hindlll

Avail Avnll

CAT

·· Avall

frngment

483 +513

+66

+332

+ 3~

+

X;:.;

p
Avail

Avall Avall

Avall

[266bp]
:T4 ligase

• 3;2

3

[151bp]

~ndll

C71bp]

(These three fragments are also labeled by
hot 32P-dATP and 32P..dCTP and are used ns
DNA probes in EMSA)
P2

klenow +4 dNTP
then T 4 ligase

CAT

-101/+332-Aexon 1-c-Myc- CA-

Fig.3 Map and steps in constructing the subcloned plasmid -101/+332-~exon 1-c-myc -CAT. The vectoc
plasmid is pBR322. The fragments used as probes in electrophoretic mobility shift assay (EMSA) and h
competition EMSA are also shown.
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Xho I-Ava II fragment

Ava II-Ava II fragment

~

b

ITCGi

kLEN~]
a-nP-dATP

I

Ava 11-Ht-d Ill fr agm•nt

~

1

cAGI

II

I

2

a! P-dCTP
dGTP
dTTP

~·

'(

=

1

laA~

AGCT

* *

*

~

CAG
~

*

Fig.4. Diagram of the DNA probes prepared. *represents cx.-32P-labeled deoxynucldotides.
All three probes were labeled by Kienow fill-in method.

c-Myc exon 1
B~mHI

P~t

NnlAh1I
I

PYu I

EcoR I
·101

Not I Xho I
P1

626bp

..

IL

Av~U Pw~I
.

P2

ltll'ld Ill

downstr•am rom t •
P2 of the- c-M c

1--~~-------------tt----~~~-.,
•1•22 •66
Piii•

Av~R

•174 I •242
•212

•332

•483 •513

23bp

-10 l /+51 '3-c-Myc-CAT

EcoRI

~

14111i1l-- 255bp

40bp

from Nu I site (•212) to
Pvu II site ( ·513) is cl4!'1ete-d
N~~I
P~t

I

EcoRI
·101

pyql

.. 111•

626bp

...

IL

NotlXhol
P1.
.
+1•22•66

•174•212

23bp

-101/+212-A-exon 1-c-Myc-CAT

40bp

Nc~IAl11I

P~tl

EcoRI
·101

Pyql

Diii..

626bp

-101/+332-A-exon 1-c-Myc-CAT

llto

IL

EcoRI

P2

P2.

NotlXt.ol
P1.
.

'

from Ava II site (•332) to
Hind msite is dele-ted
EcoRI

lf$~;~~1t:i ~~~-· ~'.'i{::1

•1•22 •66

•114 1·242

~255b~-4'-1

•212

23bp

Fig.5. The restriction maps of the three subcloned c-myc plasmids, -101/+513-c-my~-CAT,
-101/+212-Aexon 1-c-myc-CAT, and -101/+332-Aexon 1-c-myc-CAT. The deleted
parts of the two deletion mutated c-myc plasmids are also shown in this figurt;.
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AGCT

-101 /+513-c-Myc-CAT
r-i

-

-101 /+212-A-exonl-c-Myc-CAT
-101/+332-A-exonl-c-Myc-CAT

10

20

30

40

50

60

70

80

90

100

percentage of relative CAT cativity (9Q

Fig.6. The relative CAT activities (use the CAT activity of the wild-type c-myc plasmid superinfected with HSV-1as100%) of the three subclones, -101/+513-c-myc-CAT, -101/-212~exon 1-c-myc-CAT, and -101/+332-~exon 1-c-myc-CAT in two separate HSV-1 infections.
The CAT activity of 100% represents pmol chroramphenicol acetylated/mg protein/h.

-1011·513-c-M!lc-CAT

~none
................ · · · · · · .11CP4
-~·.·.······:.-:.··~~·········
..

ICP411CPO

none
-1011•332-A.eson 1-c-M!lc-CAT

;ICP4
$

ICP411CPO
ICP411CP811CP27

10

20

30

40

50

60

70

80

90

100

percentage of relative CAT cativity (%)

Fig.7. The relative CAT activities in two separate cotransfection assays (use wild type ::-myc
plasmid cotransfected with ICPO/lCP4 as 100%) for subclones -101/+513-c-myc-CAT
and -101/+332-~exon 1-c-myc-CAT. The CAT activity of 100% represents pmol chroramphenicol acetylated/mg protein/h.
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Fig.8. Results of the electrophoretic mobility shift assay (EMSA) and competition EMSA. The probes
used in this experiment are 71 bp Ava II-Hind III fragment, 151 bp Ava II-Ava II fragment, and 266 bp
Xho I-Ava II fragment, and a 164 bp fragment from VP5 promoter is used as the positive control. A nonradiolabled oligonucleotide (LBS) containing YYl binding site is used to compete with radiolabled
probes. All probes are bound with proteins in the EMSA, but only 71 bp probe is competed with LBS
(lane 4). P represents free probe.
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222 bp

DNA probes

VPS

C2 (fold, molar excess)

400

LBS (fold, molar excess)
NE (HSV uninfected, µg)
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Fig.9. Result of the competition electrophoretic mobility shift assay using unlabeled oligonucleotide C2 as
a negative control. The probe used in this experiment is a 222 bp Ava II-Hind III fragment, spanning
from the Ava II site at +332 to the Hind III site (see Fig.5). The result shows that the binding of protein
(YYl) to this probe is competed by unlabeled oligonucleotide LBS, but it is not competed by unlabeled
oligonucleotide C2 (See lane 2, 4, 6, 8,). P represents the free probe. VP5 probe is used as a control.
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A.
123

A.45

B.
6

A.

1

2

3

4

5

6 7

8

9 10 11 12 13

Fig.10 . Two separate agarose gels for the restriction analysis of the wild type c-myc plasmid -101/+513c-myc-CAT and mutated c-myc plasmid -101/+212-L'l.exon 1-c-myc-CAT. (A) Pst I digestion to generate
linear form of these two subclones (lane 4 for wild type c-myc plasmid -10 l/+513-c-myc-CAT and lane 5
for mutated c-myc plasmid -101/+212-L'l.exon 1-c-myc-CAT). Lane 3 is the Pst I digestion of -101/+212L'l.exon 1-c-myc-CAT (the size is shown in Table 4). The gel concentration is 0.9% and the running buffer
is 0.5X TBE. (B) The digestion of these two subclones by different endonuclease enzymes (lanes 2 to 7
for -101/+212-ti.exon 1-c-myc-CAT and lanes 8 to 13 for -101/+513-c-myc-CAT. Lanes 3 and 9 show the
linearization of these two plasmids by the Hind III digestion. Lanes 4, 5, 6, 10, 11 , and 12 show the Pvu
I/Hind III and EcoR I digestion to produce two bands. Lanes 7 and 13 show that the endonucleases Sma I
and Cla I can not digest these two subclones. The gel concentration is I% and the running buffer is 0.5X
TBE.
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123456

Fig.11 . The Not I-Hind III fragment is analyzed by the endonucleases Xho I, Pvu II, Alu I,Ava II, and
Hinf I. The gel concentration is 4% and the running buffer is 0.5X TBE. The undigested '.'Jot I-Hind III
fragment (the size of this fragment was previously proven to be correct) is used as size marker. The
picture shows that this fragment is only digested by Xho I to generate a 40 bp smaller fragm~nt (lane 2) .
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Fig.12 . Photograph of the mini agarose gel for the restriction analysis of the subclone -1 01/+332-~exon
1-c-myc-CAT. The gel concentration is 1% and the running buffer is 0.5X TBE. Lane l is the uncut
control. Lane 2 shows that this subclone can not be digested by Hind III . Lanes 3, 4, 6, and 8 show the
linearization of this subclone by Xho I (lane 3), Pst I (lane 4), Hind IIl/Xho I (lane 6) and Hind III/Pst l.
Lane 5 shows that the Xho l/Pst I digestion generates two bands (size shown in Table 4). Lane 10 shows
the two bands generated by Xho I/Pst I digestion. Lane 12 is the digestion by EcoR I (clearer photo is
shown in Fig.3). Lanes 5, 9, 11 , and 13 are the digestion of wild-type c-myc plasmid by Hind III (lane 5) ,
Hind III/Pst I (lane 9), Xho l/Pst I (lane 11), and EcoR I (lane 13).
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A.123

A.45

6

Fig.13. Photograph of the agarose gel for the diagnostic restriction analysis of the subclo:ied plasmids 101/+513-c-myc-CAT, IOI/+212-6exon 1-c-myc-CAT, IOI/+332-6exon 1-c-myc-CAT. The gel concentration is 1.2% and the running buffer is 0 .5X TBE. Lanes I , 2, and 3 show the EcoR I di&estion of these
three plasmids. Lanes 4, 5, and 6 show the EcoR I/Not I digestion of these three plasmids.
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